<DOC>
	<DOC>NCT02947347</DOC>
	<brief_summary>The purpose of this study is to evaluate whether the addition of ibrutinib will result in prolongation of progression-free survival (PFS) when compared with rituximab alone in treatment naïve subjects with follicular lymphoma.</brief_summary>
	<brief_title>Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, Follicular</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Histologically confirmed diagnosis of follicular lymphoma CD20+ (Grade 1, 2 or 3a) Ann Arbor Stage II, III or IV disease. Measurable disease Subjects 70 years of age or older; OR subjects 6069 years of age who have one or more comorbidities. Meets one or more Groupe d'Etude des Lymphomes Folliculaire (GELF) criteria. Adequate hematologic function within protocoldefined parameters. Adequate hepatic and renal function within protocoldefined parameters. ECOG performance status score of 02. Transformed lymphoma Prior treatment for follicular lymphoma Central nervous system lymphoma or leptomeningeal disease Currently active, clinically significant cardiovascular disease</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>